Inoperable Early Stage Non-small Cell Lung Cancer Clinical Trial
Official title:
Prediction of the Effectiveness of Hypofractionated Radiation Therapy in Early Stage Lung Cancer by Bio-imaging and Biomarkers
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice
for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or
unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy.
This has shown to result in a long term local disease control rate and a high cancer
specific survival.
The current trial addresses the issue if progression free survival (PFS) in patients treated
with radiotherapy can be predicted by a multi-variate model derived from a composite of
bio-imaging and biomarkers
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment